Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis

References

• Canadian Cancer SocietyBreast cancer statistics Available from: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=nbAccessed November 21, 2012
   Google Scholar
• ChungCTCarlsonRWGoals and objectives in the management of metastatic breast cancerOncologist2003851452014657529
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
   PubMed Web of Science ®Google Scholar
• RiveraEManagement of metastatic breast cancer monotherapy options for patients resistant to anthracyclines and taxanesAm J Clin Oncol20103317618519675449
   PubMed Web of Science ®Google Scholar
• Capecitabine (Xeloda^®) product monograph Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=61873&lang=engAccessed November 21, 2014
   Google Scholar
• AprileGMazzerMMorosoSPuglisiFPharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancerAnticancer Drugs20092021722919247178
   PubMed Web of Science ®Google Scholar
• ToiMAtiqur RahmanMBandoHChowLWThymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatmentLancet Oncol2005615816615737832
   PubMed Web of Science ®Google Scholar
• SchüllerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemother Pharmacol20004529129710755317
   PubMed Web of Science ®Google Scholar
• LeeSJChoiYLParkYHThymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerCancer Chemother Pharmacol20116874375121170649
   PubMed Web of Science ®Google Scholar
• BudmanDRMeropolNJReignerBPreliminary studies of a novel oral fluoropyrimidine carbamate: capecitabineJ Clin Oncol199816179518029586893
   PubMed Web of Science ®Google Scholar
• KamoshidaSShiogamaKShimomuraRImmunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancerOncol Rep2005141223123016211289
   PubMed Web of Science ®Google Scholar
• QuiddeJArnoldDSteinAClinical management of localized colon cancer with capecitabineClin Med Insights Oncol2012636337323170068
   PubMedGoogle Scholar
• El OmariKBronckaersALiekensSPérez-PérezMJBalzariniJStammersDKStructural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug designBiochem J200639919920416803458
   PubMed Web of Science ®Google Scholar
• YuEJLeeYRhaSYAngiogenic factor thymidime phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinomaMol Cancer Res200861554156618922971
   PubMed Web of Science ®Google Scholar
• TeoNBShokerBSJarvisCSloaneJPHolcombeCThymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breastJ Clin Pathol20035691992314645350
   PubMed Web of Science ®Google Scholar
• NagaokaHIinoYTakeiHMorishitaYPlatelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumour angiogenesis and prognosis in invasive breast cancerInt J Oncol1998134494549683777
   PubMed Web of Science ®Google Scholar
• YonenagaFTakasakiTOhiYThe expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancerPathol Int1998488508569832053
   PubMed Web of Science ®Google Scholar
• EngelsKFoxSBWhitehouseRMGatterKCHarrisALUp-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinoma in situ of the breastJ Pathol19971824144209306962
   PubMed Web of Science ®Google Scholar
• ErkusMMeteogluICulhaciNMeydanNErdogduIDoes thymidine phosphorylase correlate with angiogenesis in intraductal cancinoma of the breast?Saudi Med J2006271329133316951768
   PubMed Web of Science ®Google Scholar
• LeeAHDublinEABobrowLGAngiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breastJ Pathol199918728529010398080
   PubMed Web of Science ®Google Scholar
• YangQBarbareschiMMoriIPrognostic value of thymidine phosphorylase expression in breast carcinomaInt J Cancer20029751251711802215
   PubMed Web of Science ®Google Scholar
• NakajimaYMadhyasthaRMaruyamaM2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progressionAnticancer Agents Med Chem2009923924519199868
   PubMed Web of Science ®Google Scholar
• ToiMBandoHHoriguchiSModulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancerBr J Cancer2004902338234315150550
   PubMed Web of Science ®Google Scholar
• TwelvesCVision of the future: capecitabineOncologist20016Suppl 4353911585973
   PubMed Web of Science ®Google Scholar
• MagnéNFischelJLDubreuilAZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity rational basis for a new combination therapy with capecitabineClin Cancer Res200394735474214581344
   PubMed Web of Science ®Google Scholar
• Ait-TihyatyMRachidZMihalcioiuCJean-ClaudeBJInhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®Breast Cancer Res Treat201213321722621915635
   PubMed Web of Science ®Google Scholar
• Ait-TihyatyMRachidZLarroque-LombardA-LJean-ClaudeBJZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activityInvest New Drugs2013311409142323959266
   PubMed Web of Science ®Google Scholar
• BronckaersAGagoFBalzariniJLiekensSThe dual role of thymidine phosphorylase in cancer development and chemotherapyMed Res Rev20092990395319434693
   PubMed Web of Science ®Google Scholar
• CiccoliniJEvrardACuqPThymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde storyCurr Med Chem Anticancer Agents20044718115032715
   PubMedGoogle Scholar
• SaitoKKhanKYuSZThe predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancerLaryngoscope2009119828819117293
   PubMed Web of Science ®Google Scholar
• TakebayashiYAkiyamaSAkibaSClinicopathologic and prognostic significance of an human angiogenic factor, thymidine phosphorylase, in human colorectal carcinomaJ Natl Cancer Inst199688111011178757190
   PubMed Web of Science ®Google Scholar
• GaoJLuMYuJWLiYYShenLThymidine phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxelBMC Cancer20111117721586171
   PubMed Web of Science ®Google Scholar
• LuMGaoJWangXCShenLExpressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatinChin J Cancer Res20112328829423358102
   PubMed Web of Science ®Google Scholar
• MorelANMehtaSTaylorMARelationship of capecitabine response to thymidine phosphorylase expression and overall survival in advanced breast cancerCancer Res20107024 Suppl 2P2-09-24
   Web of Science ®Google Scholar
• LiHSuoZZhangYThe prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomasHistol Histopathol20041912913614702180
   PubMed Web of Science ®Google Scholar
• TominagaTToiMAbe O; 5′-BC Study GroupPrognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patientsClin Breast Cancer20023556412020396
   PubMedGoogle Scholar
• PuglisiFCardellinoGGCrivellariDThymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancerAnn Oncol2008191541154618441329
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134e48e7220586616
   PubMed Web of Science ®Google Scholar
• SauterGLeeJBartlettJMSlamonDJPressMFGuidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerationsJ Clin Oncol2009271323133319204209
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol20072511814517159189
   PubMed Web of Science ®Google Scholar
• TsudaHAkiyamaFKurosumiMSakamotoGReproducible immunohistochemical criteria based on multiple raters’ judgements for expression of thymidine phosphorylase in breast cancer tissueBreast Cancer Res Treat20048621522315567938
   PubMed Web of Science ®Google Scholar
• JalavaPKuopioTJuntti-PatinenLKotkansaloTKronqvistPCollanYKi67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic indexHistopathology20064867468216681683
   PubMed Web of Science ®Google Scholar
• CheangMCChiaSKVoducDKi67 index, HER2 status, and prognosis of patients with luminal B breast cancerJ Natl Cancer Inst200910173675019436038
   PubMed Web of Science ®Google Scholar
• WeigelMTDowsettMCurrent and emerging biomarkers in breast cancer: prognosis and predictionEndocr Relat Cancer201017R245R26220647302
   PubMed Web of Science ®Google Scholar
• JonatWArnoldNIs the Ki67 labelling index ready for clinical use?Ann Oncol20112250050221343384
   PubMed Web of Science ®Google Scholar
• DowsettMDunbierAKEmerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancerClin Cancer Res2008148019802619088018
   PubMed Web of Science ®Google Scholar
• FaschingPAHeusingerKHaeberleLKi67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentBMC Cancer20111148622081974
   PubMed Web of Science ®Google Scholar
• UmemuraSShiraneMTakekoshiSTokudaYMoriKOsamuraRYHigh expression of thymidine phosphorylase in basal-like breast cancers: stromal expression in EGFR- and/or CK5/6-positive breast cancersOncol Lett2010126126622966291
   PubMed Web of Science ®Google Scholar
• AndreettaCPuppinCMinisiniAThymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancerAnn Oncol20092026527118765464
   PubMed Web of Science ®Google Scholar
• BeckAEtienneMCChėradameSA role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracilEur J Cancer199430A151715227833111
   PubMed Web of Science ®Google Scholar
• EtienneMCChėradameSFischelJLResponse to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activityJ Clin Oncol199513166316707602356
   PubMed Web of Science ®Google Scholar
• IshikawaTSekiguchiFFukaseYSawadaNIshitsukaHPositive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenograftsCancer Res1998586856909485021
   PubMed Web of Science ®Google Scholar
• TakayamaTMugiyaSSugiyamaTHigh levels of thymi-dine phosphorylase as an independent prognostic factor in renal cell carcinomaJpn J Clin Oncol20063656456916861722
   PubMed Web of Science ®Google Scholar